靶向药物为急性髓系白血病（AML）治疗带来巨大进步。随着研究的深入，靶向药物治疗耐药、联合治疗不良反应叠加、缺乏有效靶点等问题亦逐渐凸显，为AML治疗策略的制订提出了新的挑战。第63届美国血液学会（ASH）年会就AML靶向药物治疗时机的选择、药物选择和联合用药等热点问题进行了报道，汇聚了全球最新临床试验成果，值得学习借鉴。“,”The treatment of acute myeloid leukemia (AML) has made a great progress in recent years owing to the emergence of targeted drugs. While the problems such as drug resistance, the increasing incidence of adverse reactions of the combined therapies, the lack of the effective therapy targets became growing concerns with the further development of studies, which has posed a big challenge to the therapy strategies of AML. This article introduces the progress of the latest clinical trial outcomes in targeted therapy for AML at the 63rd American Society of Hematology (ASH) annual meeting which reported some hot issues like options for the treatment timing of targeted therapy, the selection for the drugs and the combined drugs.